Hodgkin Lymphoma
309
62
99
127
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
64 trials with published results (21%)
Research Maturity
127 completed trials (41% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.1%
25 terminated out of 309 trials
83.6%
-3.0% vs benchmark
7%
21 trials in Phase 3/4
50%
64 of 127 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 127 completed trials
Clinical Trials (309)
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Methods of T Cell Depletion Trial (MoTD)
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
Methionine PET/CT Studies In Patients With Cancer
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma
Familial Investigations of Childhood Cancer Predisposition
Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
First in Human, Dose Escalation, Dose Expansion Study of AUR105